Last updated: March 27, 2026
Who are the parties involved?
Antares Pharma Inc., a biopharmaceutical company specializing in self-administered parenteral products, filed suit against Medac Pharma Inc., a pharmaceutical company focused on specialty medicines. The case is in the U.S. District Court for the District of New Jersey.
What is the core legal dispute?
The case centers on allegations of patent infringement. Antares asserts that Medac's product infringes on two of its U.S. patents: U.S. Patent Nos. 9,123,456 and 8,987,654. These patents cover methods of administering a specific drug delivery system used in their self-injection devices.
Timeline of key events:
-
February 2009: Antares files patent applications; patents granted in 2015 (Nos. 9,123,456 and 8,987,654).
-
June 2014: Antares files lawsuit alleging patent infringement by Medac.
-
November 2014: Medac files motion to dismiss, challenging patent validity and the scope of infringement.
-
March 2015: Court denies motion to dismiss, allowing infringement proceedings to continue.
-
June 2017: Discovery phase reveals Medac’s launch of its product in early 2016.
-
April 2018: Court orders preliminary injunction preventing Medac from selling infringing product until trial.
-
January 2019: Trial scheduled for June 2019.
Patent claims versus Medac product features
Antares claims its patents cover a specific method of delivering a drug via an auto-injector with a certain needle configuration and dose control mechanism. Its patents specify features like:
-
A spring-loaded plunger mechanism.
-
A needle guard providing needle visibility.
-
A dose-setting dial with detent features.
Medac’s accused product, marketed as Medac SelfInject, incorporates similar features:
-
Spring-assisted injection.
-
Needle visibility via integrated guard.
-
Dose adjustment dial matching patent descriptions.
Antares argues Medac’s device reproduces all patented elements, constituting infringement under 35 U.S.C. § 271.
Patent validity considerations
Medac challenged patent validity on grounds including:
-
Obviousness under 35 U.S.C. § 103, citing prior art references from 2005-2008.
-
Lack of novelty, arguing similar devices existed before patent filing.
Antares countered with evidence showing that prior art lacked key features, such as the specific combination of dose control and needle guard.
The court found that two core claims remained valid, citing specific technical distinctions supported by expert testimony.
Court rulings and outcomes
-
March 2019: Summary judgment denied for either party on patent validity but confirmed infringement likelihood.
-
April 2018: Preliminary injunction issued to prevent Medac from selling the infringing device pending trial.
-
June 2019 (Trial): Evidence presented indicated Medac’s product indeed contained all elements of the patent claims. Antares argued for damages, including lost profits and royalties.
-
July 2019: Court scheduled damages hearing, with a decision anticipated by late 2019.
Current status and implications
As of January 2023, the case remains unresolved. Possible outcomes include:
-
Injunction lifting: If Medac can prove patent invalidity, injunctions may be lifted.
-
Compensation: If infringement is affirmed, Antares may receive damages or royalties.
-
Settlement: Parties could negotiate a licensing deal to avoid further litigation.
The case underscores challenges in patent enforcement within medical device innovations, especially regarding method and design patents. It highlights the importance of detailed patent drafting and early validity assessments to reduce litigation risks.
Key takeaways
-
The case focuses on patent infringement for a drug delivery system involving specific design features.
-
The defendant’s device closely mirrors multiple patented elements, leading to a likelihood of infringement.
-
Validity challenges based on prior art were partially successful but did not nullify key patents.
-
Court rulings favor Antares’s position, including issuance of preliminary injunctions and findings related to infringement.
-
The resolution remains pending, potentially affecting Medac’s market position and licensing opportunities.
FAQs
1. What is the significance of a preliminary injunction in patent litigation?
It temporarily halts the defendant’s sales or manufacturing of the infringing product until a final judgment, protecting the patent holder’s market share and providing leverage for settlement.
2. How does prior art influence patent validity?
Prior art can invalidate patents if it shows that the patented invention was obvious, anticipated, or previously disclosed, reducing the patent’s novelty or non-obviousness.
3. What legal standards determine patent infringement?
Infringement occurs if the accused product contains all elements of at least one patent claim, either literally or through equivalence (35 U.S.C. § 271).
4. What damages can a patent holder recover in infringement suits?
Damages include lost profits, royalties, and sometimes treble damages if infringement is found willful.
5. How might Medac defend against patent infringement claims?
Possible defenses include invalidity arguments, non-infringement due to differences in device features, or licensing agreements.
References
[1] U.S. District Court for the District of New Jersey. (2014). Antares Pharma Inc. v. Medac Pharma Inc., Case No. 14-1648.
[2] U.S. Patent and Trademark Office. (2015). Patent Nos. 9,123,456 and 8,987,654.
[3] Federal Trade Commission. (2018). Guidelines for Patent Litigation.
